DOCSLIB.ORG

Dihydrotestosterone Concentration in Prostate Cancer Tissue As a Predictor of Tumor Differentiation and Hormonal Dependency1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dihydrotestosterone Concentration in Prostate Cancer Tissue As a Predictor of Tumor Differentiation and Hormonal Dependency1 [CANCER RESEARCH 38, 4349-4352, November 1978] 0008-5472/78/0038-0000$02.00 Dihydrotestosterone Concentration in Prostate Cancer Tissue as a Predictor of Tumor Differentiation and Hormonal Dependency1 Jack Geller,2 Jerry Albert, Daniel de la Vega, Debra Loza, and Woods Stoeltzing Mercy Hospital and Medical Center, Medical Research Facility, San Diego, California 92103 Abstract Materials and Methods Tissue dihydrotestosterone and 5a-reductase (A4-3-ke- Clinical. Patients with previously untreated Stage D pros tosteroid-5a-oxidoreductase) levels have been measured tate cancer who underwent transurethral resection of pros in prostates of patients with cancer and benign prostatic tate and in whom 75% or more of the resected tissue was hypertrophy; significant decreases in average values for cancer were selected for study. Tissue was utilized for both of these biochemical parameters were noted in histological study and biochemical assays. Patients were prostate cancer compared to benign prostatic hypertro followed, whenever possible, by objective parameters for phy, although individual values overlapped in both tumor responsiveness, as outlined by Schmidt ef al. (13). groups. Prostate cancer tissue dihydrotestosterone levels Antiandrogen therapy consisted of either castration, dieth- appeared to correlate better than did either histological ylstilbestrol (3 mg or more per day), or megestrol acetate tumor grading or 5a-reductase with the ultimate clinical (Megace; 160 mg/day). Parameters used to follow patients response to antiandrogen therapy. These results suggest included bone scan, prostatic acid phosphatase, and pros that assay of tissue dihydrotestosterone levels in prostate tate size. In some patients, objective data were not available cancer should be further explored as a possible marker and subjective evidence such as change in weight, pain, for tumor differentiation. appetite, and activity was utilized. Prostate DHT levels and histological grading were retrospectively correlated with Introduction tumor response. Tissue DHT and 5a-reductase (A"-3 ketosteroid-5a-oxi- Although measurement of the estrogen receptor in breast doreductase) concentrations were measured according to cancer tissue is now a well-established technique for pre previously reported methods (3). Prostate cancer was dicting responsiveness to endocrine or ablative treatment, graded histologically, with the use of a scale of 1 to 3, with a similar approach has not yet been developed for prostate 3 representing an undifferentiated tumor and 1 a well- tumors. Although there is abundant evidence that a high- differentiated tumor. affinity, low-capacity receptor protein similar to that found in the rat exists in human prostate cytosol and purified nuclei (6-10, 12), uniform detection of such a receptor in Results human BPH3 tissue has not yet been accomplished by any Comparison of 5a-Reductase and DHT Levels in Pa group that has studied more than 10 prostates (2). This is tients with Prostate Cancer and BPH. In Chart 1, it can be attributed to the difficulty of separating cytosol receptor from testosterone- and estradiol-binding globulin (7), re seen that tissue DHT levels were significantly less (p < 0.05) duction of [3H]DHT at 0-4°,the lability of DHT receptor in patients with cancer of the prostate, as compared to those with BPH, although there was a considerable overlap. complex to shearing (9) and temperature changes (9), the near saturation of endogenous cytosol receptor with DHT In 4 patients with prostate cancer (Chart 1), in whom both DHT levels and 5a-reductase were measured in the same (12), and the slow dissociation of DHT from receptor (2), negating a possible exchange assay. DHT, which can be tissue tumor samples, there was no difference in DHT levels measured in a 50-mg biopsy sample of prostate (1), may compared to those of BPH tissue, although 5<*-reductase represent a suitable alternative to the cytosol receptor as a levels were significantly reduced in 3 of these patients. biochemical marker for tissue differentiation, since DHT These 3 patients (7, 8, and 9 in Table 1), who have been levels are significantly higher in androgen target tissues followed clinically for at least 6 months, have responded than in other tissues (4). In this study, the usefulness of favorably to antiandrogen treatment. measuring DHT levels in prostate cancer tissue for predict Correlation of Tissue DHT Levels and Histological Grad ing clinical responsiveness to antiandrogen therapy has ing with Clinical Response to Therapy (Table 1; Chart 1, A been compared with histological tumor grading, the stan and B). In 9 patients with previously untreated Stage D dard technique currently being used for this purpose in prostate cancer, response to antiandrogen therapy has previously untreated patients with prostate cancer. been retrospectively correlated with both tissue DHT levels and histological grading. We have designated prostate DHT levels >2.0 ng/g as "differentiated," since this value is 1 Presented at the John E. Fogarty International Center Conference on more than 2 S.D. above the mean of non-androgen target Hormones and Cancer, March 29 to 31, 1978, Bethesda, Md. Supported by Grant 5 R26 CAÃŽ8003-02,awarded by the National Cancer Institute, Depart tissues. Histological tumor grading of 1 and 2 (Fig. '\A) was ment of Health, Education and Welfare. used to indicate well- and moderately differentiated tumors, 1To whom requests for reprints should be addressed. 3The abbreviations used are: BPH, benign prostatic hypertrophy; DHT, respectively (Figure 1X\);tumors with greater than Grade 2 17/3-hydroxy-5a-androstan-3-one. histological changes (Fig. 1B) were considered to be poorly NOVEMBER 1978 4349 Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 1978 American Association for Cancer Research. J. Geller et al. -Reduci ase A,'.. Endogenous Tissue DHT some of nature's experiments, including male pseudoher- 11109S!6 maphroditism Type II and testicular feminization, in which 5a-reductase in the former and cytosol receptor in the latter rao90807060SO403020100•A.•5± are virtually absent and prostate and male secondary sex structures are absent or ambiguous. It is presumed that DHT, the biologically active androgen in many target tis sues, is also very low in tissues of these patients. Tissue ûv.•!*-e-& DHT levels depend upon multiple factors. These include -v-••1 levels of plasma testosterone, a major substrate for DHT, b4 and 3-hydroxysteroid dehydrogenase, which removes DHT by reduction, in addition to previously mentioned 5«-reduc- 32i *••BPHA-••••AVVVÇaP<0tase and receptors. We have attempted to study the relative importance of some of these various biochemical factors as regulators of tissue DHT. In previously reported studies of patients with 0B•:•X••s BPH in which we acutely perturbed plasma testosterone, 05 Un points) 5<*-reductase, and cytosol receptor with either Megace, an p< 0 B llor A s only) antiandrogen, or polyestradiol phosphate (Estradurin), tis Chart 1..A, prostate levels of 5«-reductase for patients with BPH and sue DHT levels appeared to correlate best with change in cancer of the prostate. •¿,individualvalues for BPH; A, for cancer. Means cytosol receptor binding of DHT (5). This conclusion was are indicated by horizontal lines. B, tissue DHT levels for patients with BPH and cancer. Tissue DHT levels in 4 cancer tissues which were also assayed based on the fact that Megace and Estradurin had similar for 5a-reductase (see A in A) are shown as A, while other tissues are quantitative inhibitory effects on 5«-reductase and plasma indicated by •¿.Statisticalcomparisons of BPH and carcinoma group for both 5a-reductase activity and endogenous tissue DHT levels are shown at testosterone, but only Megace, which also decreased re the bottom of the chart. ceptor binding of DHT, significantly decreased tissue DHT levels. Table 1 In this study, we have shown in Chart 1 that among 4 Untreated prostate cancer (Stage D) patients with prostate cancer with DHT levels similar to those of the BPH group, 3 had low values of 5«-reductase DHT/g response to Patient123456''789Histologi-cal grade2232-32-332-32-32ngtissue"0.972.71.12.52.85.93.65.58.7ClinicaltherapyPartial (see Chart 1). The fact that these 3 patients responded regression6Objectivelyobjective favorably to antiandrogen therapy supports the hypothesis stable6Objective that DHT is a better biochemical marker of tumor differen progression''Partial tiation than is 5a-reductase. In 9 patients with prostate regression''Partialobjective cancer studied to date, tissue DHT also appears to correlate regression''Remission''Remission''Remission1'Partialobjective better with the ultimate response to antiandrogen therapy than histological grading (Table 1). Extension and confir mation of these studies in a much larger series of patients objective regression'' is necessary, however, before any final conclusions can be " Values > 2.0 ng/g indicate differentiated. reached. * Refers to use of objective criteria for evaluating response, It would thus appear that levels of DHT in prostate cancer including changes in bone scan, tumor mass, and prostatic acid tissue may provide a biochemical index for tissue differen phosphatase. r Lymph node replaced by prostate cancer tissue. tiation in previously untreated patients. Tumor DHT assay '' Refers to use of subjective and clinical criteria for response; also represents a practical approach to clinical limitations adequate data
Load more

Recommended publications
  • The Effects of Androgens and Antiandrogens on Hormone Responsive Human Breast Cancer in Long-Term Tissue Culture1
    [CANCER RESEARCH 36, 4610-4618, December 1976] The Effects of Androgens and Antiandrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture1 Marc Lippman, Gail Bolan, and Karen Huff MedicineBranch,NationalCancerInstitute,Bethesda,Maryland20014 SUMMARY Information characterizing the interaction between an drogens and breast cancer would be desirable for several We have examined five human breast cancer call lines in reasons. First, androgens can affect the growth of breast conhinuous tissue culture for andmogan responsiveness. cancer in animals. Pharmacological administration of an One of these cell lines shows a 2- ho 4-fold stimulation of drogens to rats bearing dimathylbenzanthracene-induced thymidina incorporation into DNA, apparent as early as 10 mammary carcinomas is associated wihh objective humor hr following androgen addition to cells incubated in serum regression (h9, 22). Shionogi h15 cells, from a mouse mam free medium. This stimulation is accompanied by an ac many cancer in conhinuous hissue culture, have bean shown celemation in cell replication. Antiandrogens [cyproterona to be shimulatedby physiological concentrations of andro acetate (6-chloro-17a-acelata-1,2a-methylena-4,6-pregna gen (21), thus suggesting that some breast cancer might be diene-3,20-dione) and R2956 (17f3-hydroxy-2,2,1 7a-tnima androgen responsive in addition to being estrogen respon thoxyastra-4,9,1 1-Inane-i -one)] inhibit both protein and siva. DNA synthesis below control levels and block androgen Evidence also indicates that tumor growth in humans may mediahed stimulation. Prolonged incubahion (greahenhhan be significantly altered by androgens. About 20% of pahianhs 72 hn) in antiandrogen is lethal.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer
    Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer Michael Danquah, Charles B. Duke, Renukadevi Patil, Duane D. Miller & Ram I. Mahato Pharmaceutical Research An Official Journal of the American Association of Pharmaceutical Scientists ISSN 0724-8741 Volume 29 Number 8 Pharm Res (2012) 29:2079-2091 DOI 10.1007/s11095-012-0737-1 1 23 Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your work, please use the accepted author’s version for posting to your own website or your institution’s repository. You may further deposit the accepted author’s version on a funder’s repository at a funder’s request, provided it is not made publicly available until 12 months after publication. 1 23 Author's personal copy Pharm Res (2012) 29:2079–2091 DOI 10.1007/s11095-012-0737-1 RESEARCH PAPER Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer Michael Danquah & Charles B. Duke III & Renukadevi Patil & Duane D. Miller & Ram I. Mahato Received: 4 February 2012 /Accepted: 9 March 2012 /Published online: 27 March 2012 # Springer Science+Business Media, LLC 2012 ABSTRACT Results CBDIV17 was more potent than bicalutamide and Purpose Overexpression of the androgen receptor (AR) and inhibited proliferation of C4-2 and LNCaP cells, IC50 for CBDIV17 anti-apoptotic genes including X-linked inhibitor of apoptosis was ∼12 μMand∼21 μM in LNCaP and C4-2 cells, respectively, protein (XIAP) provide tumors with a proliferative advantage.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibition in Prostate Cancer Cells
    ANTICANCER RESEARCH 31: 3323-3330 (2011) Combination of Resveratrol and Antiandrogen Flutamide Has Synergistic Effect on Androgen Receptor Inhibition in Prostate Cancer Cells LI KAI† and ANAIT S. LEVENSON Cancer Institute and Department of Pathology, University of Mississippi Medical Center, Jackson, MS, U.S.A. Abstract. Agents targeting the androgen receptor (AR) axis are signaling pathways (1-3). Therefore, agents other than critical for chemoprevention and treatment of prostate cancer traditional antiandrogens with the ability to inhibit AR (PCa) at all stages of the disease. Combination molecular production and block AR signaling are of great interest for both targeted therapy may improve overall efficacy. The combination chemopreventive and therapeutic strategies for all stages of PCa. of dietary compound resveratrol with known therapeutic agents, Diet-derived polyphenols are attractive clinical candidates such as the antiandrogen flutamide, may be particularly for cancer prevention and treatment because they are attractive due to the pharmacological safety of resveratrol. pharmacologically safe. Resveratrol (3,5,4’-trihydroxystilbene) Materials and Methods: Resveratrol, 5α-dihydrotestosterone is a natural phytoalexin that is synthesized in several plants as and flutamide were used in various experiments using mostly a defensive response against fungal infection and LNCaP cell line. Quantitative reverse transcription polymerase environmental stress. It is produced in the skin and seeds of chain reaction (qRT-PCR), Western blots, and luciferase assay grapes, with its further accumulation in red wine during the were utilized to examine the levels of AR mRNA, and protein fermentation process. Recently, epidemiological studies have and transcriptional activity in response to treatments. Growth demonstrated a reduced relative risk for PCa associated with proliferation assays were performed in three cell lines (LNCaP, an increased level of red wine consumption (4), which was PC3 and Du145).
    [Show full text]
  • Control of Hidradenitis Suppurativa in Women Using Combined Antiandrogen (Cyproterone Acetate) and Oestrogen Therapy
    British Journal of Dermatology (1986) 115, 269-274. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy R.S.SAWERS, VALERIE A.RANDALL* AND F.J.G.EBLING* Departments of Obstetrics and Gynaecology and "Zoology, University of Sheffield, Sheffield, U.K. Accepted for publication 12 May 1986 SUMMARY The effects of combined treatment with the antiandrogen, cyproterone acetate, and ethinyl oestradiol on four women with long-standing hidradenitis suppurativa have been investigated. The condition was controlled successfully in all patients with 100 mg/day cyproterone acetate using the reversed sequential regimen; lowering the antiandrogen to 50 mg/day caused deterioration. Before treatment, plasma testosterone levels were within the normal range, but plasma androstenedione values were raised and sex hormone binding globulin levels were low. On treatment, the androstenedione concentration fell and sex hormone-binding globulin values were raised. However, since these levels were unaltered by reducing the antiandrogen dosage, the main action of the therapy is probably that of the antiandrogen within the target cells. Hidradenitis suppurativa, or apocrine acne, is thought to occur as a result of closure of the apocrine pore with subsequent bacterial infection (Shelley & Cahn, 1955); androgens have been implicated in its aetiology (see, for example, Brunsting, 1952). Since acne, an androgen-dependent condition also involving pore occlusion and bacterial infection, responds to combined cyproterone acetate and oestrogen therapy (Neumann, Aydinlik & Lachnit-Fixson, 1984), we have investigated the effect of such treatment on four women with long-standing hidradenitis suppurativa. Although the antiandrogen is the most effective component of such treatment for hirsutism (Sawers, Randall & Iqbal, 1982), cyproterone acetate must be given to women of reproductive age in conjuction with oestrogen to ensure contraception so that the possible feminization of a male foetus is avoided.
    [Show full text]
  • Receptor Af®Nity and Potency of Non-Steroidal Antiandrogens: Translation of Preclinical ®Ndings Into Clinical Activity
    Prostate Cancer and Prostatic Diseases (1998) 1, 307±314 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pcan Review Receptor af®nity and potency of non-steroidal antiandrogens: translation of preclinical ®ndings into clinical activity GJCM Kolvenbag1, BJA Furr2 & GRP Blackledge3 1Medical Affairs, Zeneca Pharmaceuticals, Wilmington, DE, USA; 2Therapeutic Research Department, and 3Medical Research Department, Zeneca Pharmaceuticals, Alderley Park, Maccles®eld, Cheshire, UK The non-steroidal antiandrogens ¯utamide (Eulexin1), nilutamide (Anandron1) and bicalutamide (Casodex1) are widely used in the treatment of advanced prostate cancer, particularly in combination with castration. The naturally occurring ligand 5a-DHT has higher binding af®nity at the androgen receptor than the non-steroidal antiandrogens. Bicalutamide has an af®nity two to four times higher than 2-hydroxy¯utamide, the active metabolite of ¯utamide, and around two times higher than nilutamide for wild-type rat and human prostate androgen receptors. Animal studies have indicated that bicalutamide also exhi- bits greater potency in reducing seminal vesicle and ventral prostate weights and inhibiting prostate tumour growth than ¯utamide. Although preclinical data can give an indication of the likely clinical activity, clinical studies are required to determine effective, well-tolerated dosing regimens. As components of combined androgen blockade (CAB), controlled studies have shown survival bene®ts of ¯utamide plus a luteinising hormone-releasing hormone analogue (LHRH-A) over LHRH-A alone, and for nilutamide plus orchiectomy over orchiectomy alone. Other studies have failed to show such survival bene®ts, including those comparing ¯utamide plus orchiectomy with orchiectomy alone, and nilutamide plus LHRH-A with LHRH-A alone.
    [Show full text]
  • Exposure to the Antiandrogen Flutamide
    Disturbed testicular descent in the rat after prenatal exposure to the antiandrogen flutamide P. van der Schoot Department of Endocrinology and Reproduction, Faculty of Medicine and Health Sciences, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands Summary. Exposure of rats in utero to the anti-androgen flutamide resulted in feminization of the external genitalia that was noticeable at birth. This exposure also resulted in a high degree of cryptorchidism during adulthood. In most affected animals, testes were lying in 'ovary position' close to the caudal pole of the ipsilateral kidney. Cryptorchidism occurred despite normal prenatal development of the gubernacular cones and the transformation of these structures, postnatally, into muscular cremaster sacs. Inter- and intralitter variation in the response to prenatal exposure to flutamide was observed as well as intra-individual variation. Cryptorchidism frequently occurred unilaterally with right side cryptorchidism predominating. Cryptorchidism occurred in association with marked suppression of the growth of the ipsilateral epididymis and deferent duct. The possibility is considered that the poor development or absence of these structures contributes to cryptorchidism. Intra\x=req-\ individual variation supports the concept of the local nature of the influence of testis hormones in stabilization and further differentiation of the ipsilateral Wolffian duct derivatives. Cryptorchidism was enhanced when rats were treated postnatally with testosterone or oestradiol. The effect of testosterone was unexpected in view of the generally held hypothesis that androgens enhance testis descent. The effect of oestradiol was as expected: other animal models have been described in which induction of cryptorchidism by oestradiol occurs. Additional treatment with oestradiol caused further suppression of growth of the epididymis and deferent duct.
    [Show full text]
  • Activity and Endocrinological Novel Antiandrogen, TZP-4238
    Endocrine Journal 1994, 41(4), 445-452 Antiandroenic~Activity and Endocrinological Profile of a Novel Antiandrogen, TZP-4238, in the Rat MAMORUMIEDA, YOSHIHIROOHTA, T0M0YUKI SAITO, HIROO TAKAHASHI, EIICHIROSHIMAZAWA ANDKATSUHIKO MIYASAKA PharmacologicalResearch Department, Teikoku Hormone Mfg. Co., Ltd., Kawasaki213, Japan Abstract. TZP-4238 is a new potent, orally active steroidal antiandrogen. Antiandrogenic activity and endocrinological profile of TZP-4238 were investigated in rats, except that progestational activity was determined in rabbits. TZP-4238 suppressed the testosterone propionate-induced increases in the weights of the ventral prostate, seminal vesicle and levator ani in castrated immature male rats. TZP- 4238 also decreased the weights of the ventral prostate, seminal vesicle and levator ani in intact adult male rats, but did not affect the weight of the testis or the serum concentrations of luteinizing hormone and testosterone. TZP-4238 did not have such an inhibitory effect on the weight of the adrenal gland as seen in other steroidal antiandrogens. It exhibited potent progestational activity. Although TZP-4238 did not exert androgenic or estrogenic activity, it had weak antiestrogenic activity. These results suggest that TZP-4238 exerts an antiandrogenic effect on the prostate without any compensatory change in the serum concentration of luteinizing hormone or testosterone in rats, and it is a useful drug for the treat- ment of androgen-dependent diseases such as prostatic hypertrophy and prostatic cancer. Key words: TZP-4238, Antiandrogenic activity, Endocrinological profile. (Endocrine Journal 41: 445-452,1994) ONE OF THE main mechanisms of antiandrogenic cyproterone acetate, megestrol acetate (MS) and action is the competition with androgen for the an- chlormadinone acetate (Prostal®) do not induce drogen receptor in the target organ.
    [Show full text]
  • Product Monograph Casodex®
    PRODUCT MONOGRAPH Pr CASODEX® bicalutamide tablets 50mg Tablets Non-Steroidal Antiandrogen AstraZeneca Canada Inc. Date of Revision: 1004 Middlegate Road July 13, 2017 Mississauga, Ontario L4Y 1M4 www.astrazeneca.ca Control No. 205811 CASODEX® is a registered trademark of AstraZeneca UK Limited, used under license by AstraZeneca Canada Inc. COPYRIGHT 1995-2017 ASTRAZENECA CANADA INC. Page 1 of 32 TABLE OF CONTENTS TABLE OF CONTENTS .........................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION......................................................................3 INDICATIONS AND CLINICAL USE ...........................................................................3 CONTRAINDICATIONS.................................................................................................3 WARNINGS AND PRECAUTIONS ...............................................................................4 ADVERSE REACTIONS .................................................................................................8 DRUG INTERACTIONS ...............................................................................................12 DOSAGE AND ADMINISTRATION ...........................................................................13 OVERDOSAGE..............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY..........................................................14
    [Show full text]
  • Downloaded from Bioscientifica.Com at 10/11/2021 05:04:53AM Via Free Access 66 H
    COMPARISON OF THE EFFECTS OF CYPROTERONE, CYPROTERONE ACETATE AND OESTRADIOL ON TESTICULAR FUNCTION, ACCESSORY SEXUAL GLANDS AND FERTILITY IN A LONG-TERM STUDY ON RATS H. STEINBECK, M. MEHRING and F. NEUMANN Experimental Research Pharma, Schering AG, Department of Endocrinology, 1 Berlin 65 {Received \5th August 1970) Summary. Treatment of adult male rats with oestradiol, cyproterone acetate or cyproterone affected spermatogenesis, accessory sexual glands and fertility in different ways. Suppression ofLeydig cells, spermatogenesis, accessory sexual glands and fertility ran parallel in oestradiol-treated ani- mals. High doses of cyproterone acetate caused severe suppression of the accessory sexual glands and fertility but had only a slight inhibitory influ- ence on spermatogenesis, Leydig cells were only temporarily affected. With high doses ofcyproterone, Leydig cells were over-stimulated initially but returned to normal appearance during treatment. There was almost no effect on spermatogenesis but the accessory sexual gland weights and fertility were markedly reduced. Recovery from any changes was rapid after cessation of cyproterone acetate and cyproterone treatment but not after oestradiol. Lower doses of cyproterone acetate and cyproterone did not affect testicular morphology but significantly depressed the accessory sexual gland weights. Different mechanisms of action for the three steroids are discussed. Objections are raised against the use of cyproterone acetate for the control of male fertility. INTRODUCTION Accessory sexual gland function as well as sexual behaviour are among the processes that are maintained by the action of testicular androgens in male mammals including man. Prevention of access by androgens to these targets, either surgically or chemically, results in impairment or even abolition of their normal function.
    [Show full text]
  • Spironolactone
    SPIRONOLACTONE http://www.aocd.org Spironolactone is currently being used in dermatology as an antiandrogen or anti-male hormone therapy for the treatment of acne, diffuse hair loss in females, and hirsutism. This drug has a minor estrogen effect on the scalp, hair, skin and body. Acne improves within 2 to 4 months and skin oiliness decreases. The dose of spironolactone for acne in females is 50 - 150mg a day for at least 1 to 2 years with periodic rest periods, to determine if the drug is still needed. Hirsutism or increased facial and body hair is treated with doses of 100 - 200mg a day for 2 years with minimal rest periods. The first change in the body hair is decreased growth rate, then finer hair and ultimately decreased hair. The specific actions of spironolactone as an antiandrogen are not well understood. It appears to act at two sites: it blocks androgens at the hair follicle/sebaceous gland and it reduces the secretion of androgens from the adrenal gland. To check the effectiveness of this therapy, the hair growth and/or acne are assessed at 2 to 4 month intervals. Spironolactone is an antihypertensive drug which does not affect the blood pressure of those with normal blood pressure. Contraindications: Spironolactone should not be used by pregnant women. The drug should be used only in conjunction with reliable birth control. Spironolactone should also not be used by patients with significant impairment of kidney function. Side Effects: Mild gastrointestinal upset or headache may occur. Urticaria (hives) occur rarely. As a diuretic, spironolactone can increase urination and induce disturbances in fluid and electrolyte balance with increased potassium levels.
    [Show full text]